STOP
Suicidality: Treatment Occurring in Paediatrics
| Coordinatore | KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 3˙748˙810 € |
| EC contributo | 3˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-11-01 - 2015-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | coordinator | 1˙119˙023.20 |
| 2 |
HEALTHTRACKER LTD
Organization address
address: Foxon Close 18 contact info |
UK (Caterham) | participant | 305˙420.00 |
| 3 | Concentris Research Management GmbH | DE | participant | 300˙467.53 |
| 4 |
FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA
Organization address
address: CARRER ROSSELLO 149-153 contact info |
ES (BARCELONA) | participant | 184˙891.12 |
| 5 |
UNIVERSITA DEGLI STUDI DI CAGLIARI
Organization address
address: VIA UNIVERSITA 40 contact info |
IT (CAGLIARI) | participant | 165˙745.53 |
| 6 |
True Clarity Limited
Organization address
address: "Londonderry Farm, Keynsham Road, The Hay Barn" contact info |
UK (Willsbridge) | participant | 143˙610.00 |
| 7 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 113˙941.00 |
| 8 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 109˙900.05 |
| 9 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 100˙294.16 |
| 10 |
CENTRO DE INVESTIGACION BIOMEDICA EN RED
Organization address
address: CALLE MONFORTE DE LEMOS 5 contact info |
ES (MADRID) | participant | 85˙896.49 |
| 11 |
"THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON"
Organization address
address: Brunswick Square 29-39 contact info |
UK (LONDON) | participant | 85˙000.00 |
| 12 |
ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT
Organization address
address: Square J 5 contact info |
DE (MANNHEIM) | participant | 71˙775.90 |
| 13 |
UNIVERSITY OF DUNDEE
Organization address
address: Nethergate contact info |
UK (DUNDEE) | participant | 60˙231.22 |
| 14 |
CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
Organization address
address: Avenue du Doyen Gaston Giraud 191 contact info |
FR (MONTPELLIER) | participant | 47˙766.96 |
| 15 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 41˙006.00 |
| 16 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | participant | 37˙058.02 |
| 17 |
ACADEMISCH ZIEKENHUIS GRONINGEN
Organization address
address: Hanzeplein 1 contact info |
NL (GRONINGEN) | participant | 27˙972.82 |
| 18 |
Great Ormond Street Hospital for Children NHS Trust
Organization address
address: Great Omond Street contact info |
UK (LONDON) | participant | 0.00 |
| 19 |
UNIVERSITY OF ALBERTA
Organization address
address: 114 ST - 89 AVE contact info |
CA ("EDMONTON, ALBERTA") | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The emergence of suicidality in patients receiving drug treatment is of concern because of the overall burden and the possible link with completed suicide. The lack of uniform requirements for defining, detecting and recording suicidality and the presence of disease related confounders create major problems. It is possible that Medication-Related Suicidality (MRS) differs from Psychopathology-Related Suicidality (PRS) in terms of phenomenology, clinical expression and time course, and may vary between children and adults. Unlike PRS, the time-course of MRS may be associated with possible differences in drug pharmacokinetics; abrupt onset; absence of suicidality prior to start of medication; and emergence of suicidality related co-morbidities after treatment. This proposal will focus on developing a web-based comprehensive methodology for the assessment and monitoring of suicidality and its mediators in children and adolescents using the HealthTrackerTM (a paediatric web-based health outcome monitoring system), with the aim of developing a Suicidality Assessment and Monitoring Module, a Bio-psycho-social Mediators of Suicidality Assessment Module, and a Suicidality-Related Psychiatric and Physical Illness Module. The information obtained will be used to computer-generate classification of suicidality using the Classification of Suicide-Related Thoughts and Behaviour (Silverman et al, 2007) and the Columbia Classification Algorithm of Suicidal Assessment (C-CASA) (Posner et al, 2007). The existing Medication Characteristics Module will be expanded to allow documentation of pharmacological characteristics of medication, to explore whether they mediate MRS. The methodology will then be tested in 3 paediatric observational trials (risperidone in conduct disorder; fluoxetine in depression, and montelukast in bronchial asthma) and standardized, which can be used pharmacovigilance and in epidemiological, observational, and registration trials.'
Introduzione (Teaser)
Detecting suicidal tendencies in children and adolescents on medications can be challenging. Researchers are testing a web-based tool to identify those at risk.
Descrizione progetto (Article)
Through the'Suicidality: Treatment occurring in paediatrics' (STOP) project, an assessment and monitoring tool has been developed. It will be tested with three groups of children and adolescents.
The first group consists of 400 children and adolescents on antipsychotic medication. The second group is made up 240 patients taking antidepressants. The third group of 200 is on asthma medication. The effectiveness of this tool will be compared to the Columbia Classification Algorithm of Suicidal Assessment (C-CASA), considered the gold standard.
As part of the STOP study, researchers designed a methodology for detecting signals of suicide-related adverse events (SRAEs) related to medications. The methodology was developed based on data from previously conducted large-scale studies.This tool has great potential.
It can be used when children and adolescents start taking a new medication. If certain side effects are correlated with suicidal tendencies, it may be possible to be on the lookout for those indications. The tool also can be used to monitor suicidal tendencies in routine clinical care.
There is the possibility that the final web-based system can be modified for hand-held computers such as IPads, as well as for mobile phones.
Such innovations will make the tool even more user-friendly.
The tool has already contributed to the field. Recommendations on how to report serious side effects have been published in the literature. The team will also be able to help in the collection of biological data from other studies. As a result, the causes of suicidal tendencies may be better understood.
Over time, findings from STOP research may allow clinicians to identify high-risk groups. Then prophylactic interventions can be used in multiple settings, saving lives.